1_1_right_clean


EMAIL NOT DISPLAYING - CLICK HERE TO VIEW IN YOUR BROWSER

 
 
THE SABIN REPORT VOLUME 14 ISSUE 2

Introducing the New Sabin Website


We are excited to announce the launch of the new Sabin.org. The changes are more than just an updated look; we hope that you find our new site an engaging way to learn about our mission, programs and the public health issues we are aiming to improve.  We encourage you to visit the site and appreciate your interest in our work.


Clinical Testing of Sabin’s Human Hookworm Vaccine Advances

On November 5, the Sabin Vaccine Institute announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing the first human hookworm vaccine.  Part II of the trial commenced in Americaninhas, Brazil, following successful vaccinations in Part I of the study, which began in Belo Horizonte, Brazil

 

in late 2011. The trial will enroll 66 healthy, hookworm-exposed adults between the ages of 18 and 45.

“Because the hookworm-exposed population being vaccinated in Part II of this trial is representative of the eventual target population, we’re closer to making this goal a reality,” said Dr. David Diemert, the trial’s principal investigator.

Earlier this year, the Sabin Vaccine Institute, in partnership with the George Washington University and the Children’s National Medical Center, began vaccinating participants for a parallel Phase 1 clinical trial in Washington, DC. A critical component of the vaccine being tested is a new adjuvant developed by the Infectious Disease Research Institute (IDRI) of Seattle, Washington. The adjuvant, GLA-AF, could potentially help stimulate the immune system for an improved specific antibody response to the vaccine antigen. Read more here.

Uniting to Combat Neglected Tropical Diseases: Translating the London Declaration into Action


On November 16—18, the Bill & Melinda Gates Foundation and The World Bank hosted “Uniting to Combat Neglected Tropical Diseases: Translating the London Declaration into Action.”

The meetings brought together NTD partners from around the world to discuss progress since the January 30, 2012 London Declaration and build on the pledges made by various partners, including pharmaceutical companies, national governments and NGOs to control or eliminate the most common NTDs by 2020.

To kick off this event, the Global Network chaired a roundtable that included current NTD donors and supporters as well as other bilateral representatives and foundations that are relatively new to the NTD community. The group discussed the major progress that had been towards NTD control and elimination as well as opportunities for new supporters to become involved to help meet our 2020 goal.

Following this event, the World Bank hosted an opening reception featuring remarks by newly appointed World Bank president, Dr. Jim Yong Kim.

Dr. Kim noted, “Tackling these diseases in a coordinated way saves lives and money, and requires expanding lessons that we have learned from our efforts to eliminate river blindness—first, a simple community health system approach, and second, partnerships with pharmaceutical companies for free supply of [treatments].”

The weekend continued with several panels and side meetings to discuss research and development, resource mobilization techniques, effective collaboration and innovation, and action items for the future. On Sunday morning, the Global Network’s communication director, Richard Hatzfeld chaired a breakout session on NTD advocacy and how to build public awareness for our issue.

Financial Times Special Report:  Combating Neglected Diseases


On October 11, the Financial Times published a special report, entitled “Combating Neglected Diseases.” The report contains in-depth stories and interviews featuring several of Sabin’s key programs, including Sabin Vaccine Development, the Global Network for Neglected Tropical Diseases and the Dengue Vaccine Initiative.

 


The report covers a wide spectrum of issues related to neglected tropical diseases (NTDs), including their economic burden, the need for improved treatment methods, the need for R&D funding and the importance of bilateral and multilateral engagement.

You can download a PDF from the Financial Times website


New Global Vaccine Action Plan Brings World Closer to Universal Access to Immunization


On May 25, representatives at the 65th World Health Assembly gave their support to a new Global Vaccine Action Plan (GVAP). The GVAP is the product of an 18-month consultation process involving input from more than 1,100 individuals in 140 countries (representing 290 distinct organizations). This remarkable effort was coordinated by the Decade of Vaccines (DoV) Collaboration, a group of leading international vaccine experts representing the collective vision to extend the full benefits of immunization to all people everywhere.



Sabin Executive Vice President Dr. Ciro de Quadros played a pivotal role in the plan’s development by serving as the Co-chair of the DoV Collaboration


Steering Committee, the driving force behind the drafting of the GVAP.

WHA endorsement of the GVAP marks a major milestone towards universal access to immunization. You can read Sabin’s statement of support for the GVAP at the link here.


USAID and Partners Honor International NTD Champions and Congressional Advocates


On September 19, USAID and more than 40 non-governmental organizations, academic institutions, global health leaders, civil society groups and pharmaceutical companies gathered in the Russell Senate Office Building to celebrate the numerous successful partnerships that have led to advances in NTD treatment and control.

Dr. Neeraj Mistry, Managing Director of the Global Network, helped to kick off the event, “Celebrating an Untold Story of Success: Global Partnerships in the Fight against NTDs,” by sharing the END7 Campaign’s “Mission in a Minute” video, which is part of the Global Network’s effort to raise public awareness about the seven most common NTDs.

Continue reading this blog post to see highlights from the event.


Dr. Ariel Pablos-Mendez (center) with the four NTD champions, Dr. Nana Biritwum (left), Dr. Mwele Malecela (center left), Dr. Uche Amazigo (right), Dr. Adetokunbo "Ade" Lucas (center right) 


Wave of Celebrity Support for END7

On July 31, celebrities from around the world called on their fans and followers to join the END7 campaign, a global effort to control and eliminate seven neglected tropical diseases (NTDs) by 2020. Music, entertainment and fashion stars, including Katy Perry,  Slash, Ewan McGregor, Stella McCartney, Tom Felton, Alyssa Milano, Danny DeVito, Amos Lee, Norah Jones, MC Hammer, Aaron Neville, The Kooks, Rosanne Cash and many others reached out to their Twitter and Facebook fans to help END7 raise awareness about these devastating diseases of poverty that infect one in six people worldwide.

All together as many as 50 million people learned how easy it is to treat and prevent NTDs! See the full list of celebrity supporters here.


In Berlin, Industry and NGOs Share Joint Progress on Neglected Tropical Disease Control


On September 27, global health advocates, World Health Organization, the Bill & Melinda Gates Foundation and the pharmaceutical industry came together to discuss strategies for improved collaboration and increased private sector involvement in



His Excellency John A. Kufuor and Dr. Neeraj Mistry

neglected tropical disease (NTD) treatment and control programs.  During a workshop in Berlin, Germany, experts exchanged new ideas and called for expanded partnerships in order to meet WHO targets to control and eliminate the most common NTDs by 2020.

The workshop evaluated progress made since the “London Declaration,” including drug donations from pharmaceutical companies, donor government support for NTD programs, and new research and development initiatives. British MP and Sabin Foundation Europe trustee Jeremy Lefroy moderated the “Best Practices” session highlighting the contributions of Merck KGaA, EISAI, Sanofi, and Bayer Healthcare AG. The group also discussed the need for new partnerships between the private sector and non-governmental organizations (NGOs) in order to create treatment models that will ultimately allow endemic countries to manage their NTD programs. To conclude the events, His Excellency John A. Kufuor, President of the Republic of Ghana (2001-2009) and Special Envoy for Neglected Tropical Diseases, was featured as the evening keynote speaker addressing an audience of over 140 distinguished guests including representatives from the German parliament and African diplomatic corps

“Today’s event reminds us that great progress has already been made in the work to eliminate NTDs,” said President Kufuor. “The current partnerships among civil society groups, multilateral organizations, governments and the private sector will serve as a roadmap moving forward and will support further  engagement by  the private sector—beyond the pharmaceutical companies— in NTD programs in Africa, Asia and Latin America.” 

A number of news sources picked up the news, including Deutsche Welle. Read the full press release here.

Sabin Kicks Off Participation in ProVac's International Working Group


Sabin has recently initiated a partnership with the ProVac Initiative’s International Working Group. The ProVac Initiative provides technical support to decision makers and strengthens national capacity to conduct economic analyses and make evidence-based decisions for the introduction of new vaccines.

The Initiative was established by PAHO in 2006 in the region of the Americas and has provided support for the evaluation of pneumococcal, rotavirus and HPV vaccines in more than 14 countries.  In response to requests from non-PAHO countries, ProVac has established an International Working Group (IWG) as a pilot program which aims to transfer tools, methods and lessons learned from the PAHO ProVac Initiative to other WHO member countries.

As a member of the ProVac IWG, Sabin is developing a strategy and a practical guide to aid countries in effectively communicating evidence to stakeholders. The Sabin team recently accompanied the ProVac team to San Jose, Costa Rica as they provided technical support to Costa Rica’s multidisciplinary team conducting a cost-effectiveness analysis of pneumococcal conjugate vaccine. During the visit, Costa Rica’s team presented their cost-effectiveness analyses results to the Minister of Health and key individuals from the office of Social Security.

The Sabin team also participated in and facilitated a session at the IWG Euro Workshop led by Agence de Médecine Préventive (AMP) and the WHO Euro regional team in Dubrovnik, Croatia on October 16-18, 2012. The primary objective of this workshop was to provide training on cost-effectiveness analyses, hands-on experience with the ProVac models and to serve as an introduction for three middle-income countries that are planning to perform a cost-effectiveness analyses on the pneumococcal vaccine. There were 29 workshop participants from Albania, Croatia, Estonia and Georgia. Also in attendance were partners from AMP, WHO Euro, WHO HQ, PAHO ProVac and Sabin.


Multilevel Advocacy Efforts for Sustainable Immunization Financing (SIF) in Uganda


Following a Sabin-sponsored briefing last February, Uganda formed a Parliamentary Forum on Immunization, and since then advocacy activities for sustained immunization financing have intensified on several levels. Here are some highlights:

  • In April, the 126th International Parliamentary Union (IPU) Assembly produced a resolution: “Access to health as a basic right: the role of parliaments in addressing key challenges to securing the health of women and children.” Proceedings of an informal session on immunization are available here.
  • Ugandan parliamentarians met with local government chairpersons, district health officers, federal officials and WHO, UNICEF and USAID counterparts to discuss immunization and immunization financing at the grassroots level.  The event, which took place on April 2-3 and drew over 300 participants, was organized by Sabin and the Uganda Local Government Association (ULGA). For more on the ULGA meeting, click here.
  • At the Uganda National Assembly, parliamentarians discussed immunization challenges and shortfalls. A letter signed by over 100 MPs was sent to President Museveni, calling for greater government commitment to the national immunization program.
  • These advocacy efforts are paying off.  In his State of the Nation Address on June 7, President Museveni acknowledged the need to increase financing to support local governments in the next fiscal year budget.


Hon Huda Oleru welcomes SIF peer exchangers from Sierra Leone and Nepal to the Ugandan Parliament.

  

Eisai and the Sabin Vaccine Institute Partner to Develop Vaccines for Chagas Disease and Leishmaniasis


On September 12, The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) announced a new collaboration with pharmaceutical company Eisai Co., Ltd. This new partnership represents an important first step in what will be an ongoing effort to find solutions to some of the world’s most pervasive diseases of poverty.

Eisai’s adjuvant material donation will enable the Sabin PDP to expand ongoing research and development for its leishmaniasis and Chagas disease vaccine candidates.

"As a global company in human health care, we see this partnership and co-development of NTD vaccines as a long-term investment to improve the health outcomes for developing countries,” said Dr. BT Slingsby, Director of Global Access Strategy at Eisai Co., Ltd.

Both Sabin and Eisai issued press releases. Click to learn more.


CaT Highlights Growing Typhoid Pandemic in Asia


On June 13 in Bangkok, Thailand, the Coalition against Typhoid (CaT) brought together global health leaders from across Asia to discuss the high burden of endemic typhoid and the growing number of typhoid outbreaks in the region. Experts called on policymakers and ministries of health to make typhoid vaccination a priority in their countries.

Despite a WHO recommendation and the prioritization of typhoid vaccines for “immediate” implementation at a 2009 WHO SEARO meeting, many countries in Asia have yet to recommend or introduce typhoid vaccines. The panelists emphasized the need for improved surveillance and control programs throughout the region, noting that in order to have the greatest impact, typhoid vaccination efforts must be implemented in conjunction with other public health programs, such as access to safe drinking water and the promotion of good hygiene practices, including hand washing.

Read the full press release here, and visit Facebook to see photos from the event.

You may also be interested in reading about how pediatricians are helping to advocate for greater typhoid immunization in Asia. Read the press release here.



From left: Dr. Chris Nelson, Dr. Vipin M. Vashishtha, Professor Lalitha Mendis, Dr. Jeremy Farrar, Dr. Nguyen Van Cuong, Dr. Shyam Raj Upreti
 

Forbes Hosts Art Show to Benefit Sabin Programs


On May 8 and 10, the Sabin Vaccine Institute and Forbes magazine hosted events at the Forbes’ galleries in New York City featuring the photography of Elizabeth Jordan. Event co-hosts included Meredith Kopit Levien, Chief Revenue Officer of Forbes; Moira Forbes, Publisher of ForbesWoman; and Alisa Swidler, Board Member of the Sabin Vaccine Institute. More than 250 people attended the events, including prominent


 
"Albert", by Elizabeth Jordan
guests Donna Karan and 1999 Miss Universe Mpule Kwelagobe of Botswana. Proceeds from art sales went to the Sabin Vaccine Institute to support its programs.

The event took place thanks to the generous support of Forbes, Stoli Elit and Aaron Basha. Please see the show catalog to view Elizabeth Jordan photography currently on sale to benefit Sabin. For more information or to make an art purchase, please contact Tara Hayward at tara.hayward@sabin.org or 202-683-1881.


Baylor College of Medicine Receives more than $6 million from NIH to Develop SARS Vaccine


On May 22, Baylor College of Medicine (BCM) announced that they will receive up to $6.2 million over five years from the National Institute Of Allergy and Infectious Diseases, to develop a vaccine for severe acute respiratory syndrome (SARS). The research and development will be done in partnership with Sabin Vaccine Institute, among others.

Vaccines in the past have actually exacerbated the SARS infection. Vaccine development researchers will work to get around the problem by stimulating neutralizing antibodies to block the attachment of the virus to its receptor. The vaccine would be used to prevent potential SARS outbreaks as well as for biodefense preparedness.


Sabin Welcomes the Newest Members of its Staff
  • Dr. Larry Ellingsworth, Vice President and Product Development Partnership Deputy Director
  • Peter Carrasco, Director, International Association of Immunization Managers Secretariat
  • Diane Coraggio, Senior Program Officer, ProVac
  • Khongorzul Dari, Senior Program Officer, Sustainable Immunization Financing
  • Katherine Delisio, Senior Program Officer, International Association of Immunization Managers Secretariat
  • Maylene Leu-Bent, Grants and Contracts Manager, Vaccine Development
  • Rachel Forst,  Resource Development Operations Coordinator
  • Alison Maassen, Program Coordinator, International Association of Immunization Managers Secretariat
  • Kelsey Souleret, Staff Accountant
Also Inside:

Clinical Testing of Sabin’s Human Hookworm Vaccine Advances

Uniting to Combat Neglected Tropical Diseases: Translating the London Declaration into Action

Financial Times Special Report:  Combating Neglected Diseases

New Global Vaccine Action Plan Brings World Closer to Universal Access to Immunization

USAID and Partners Honor International NTD Champions and Congressional Advocates

Wave of Celebrity Support for END7

In Berlin, Industry and NGOs Share Joint Progress on Neglected Tropical Disease Control

Sabin Kicks Off Participation in ProVac's International Working Group

Multilevel Advocacy Efforts for Sustainable Immunization Financing (SIF) in Uganda


Eisai and the Sabin Vaccine Institute Partner to Develop Vaccines for Chagas Disease and Leishmaniasis

CaT Highlights Growing Typhoid Pandemic in Asia

Forbes Hosts Art Show to Benefit Sabin Programs

Baylor College of Medicine Receives more than $6 million from NIH to Develop SARS Vaccine

New to Our Team


Donor support is critical to Sabin’s innovation in the development of new technologies and control measures to reduce human suffering from poverty-promoting disease through novel, non-profit vaccine development and effective advocacy. The Sabin Vaccine Institute has been ranked as a “4 Star Charity” by Charity Navigator for five consecutive years – placing it among the top 5 percent of more than 5,100 charities ranked worldwide for transparency and fiscal responsibility. Please consider making a donation to help us advance these efforts. Thank you for your support! 

Sabin Joins Texas Medical Center



The Sabin Vaccine Institute is proud to become the fifty first member of the Texas Medical Center, the world’s largest medical complex. This collaboration among institutions represents an extraordinary opportunity to make an important difference in global health. Please see the press release to learn more.

19th Annual Albert B. Sabin Gold Medal Award Ceremony

On May 7, the Sabin Vaccine Institute presented Dr. F. Marc LaForce with the 19th annual Albert B. Sabin Gold Medal Award. Leaders from across the global health community joined us at the ceremony to honor Dr. LaForce for his contributions to the development of a new vaccine for epidemic meningitis in Africa.

From 2001 to 2012, Dr. LaForce served as the Director of the Meningitis Vaccine Project (MVP), a partnership between PATH and the World Health Organization funded by the Bill & Melinda Gates Foundation. Continue reading the press release here, and visit Sabin’s Gold Medal Award page to learn more about the Gold Medal Award.

BBVA Awards Ceremony recognizes Dr. Ciro de Quadros


The presentation ceremony of the BBVA Foundation Frontiers of Knowledge Awards took place on June 21 in the Marqués de Salamanca Palace, Madrid. Sabin Executive Vice President Dr. Ciro de Quadros received the BBVA Frontiers of Knowledge Award in Development Cooperation for leading the efforts to eliminate measles and polio from the Western hemisphere and for his central role in the eradication of smallpox worldwide. Please see the press release and more photos from the event here.

Sabin’s 2011 Annual Report

In September, we released our 2011 annual report, detailing the significant accomplishments of our programs from the past year. 

You can read an online version of our annual report here.

Sabin in the News

Earlier this year Sabin President Dr. Peter Hotez was a featured guest on Soledad O’Brien’s CNN morning show “Starting Point.” If you missed his segment on the burden of NTDs globally and in the U.S., or if you’d like to see it again, watch it here.

Dr. Neeraj Mistry shared his views on the way forward for NTD control and elimination, including the importance of public awareness campaigns, like END7,  and community building as a way to increase support for NTD programs in a November 27story published in The Guardian entitled “Putting Neglected Tropical Diseases under Spotlight.”

The Voice of America featured an article on Former President of Ghana, John A. Kufuor, who joined the Sabin Vaccine Institute as the new neglected tropical disease (NTD) Special Envoy in mid-April.

Celebrities from around the world called on their fans and followers to join the Global Network’s END7 campaign, a global effort to eliminate seven neglected tropical diseases (NTDs) by 2020. This prompted an article on the MTV website regarding Katy Perry’s twitter support for the campaign.

Dr. Peter Hotez wrote an op-ed for the New York Times in August on the rise of NTDs in the United States, a point which was then highlighted in articles in Time and the Economist on the threat of West Nile virus.

Sabin Executive Vice President Dr. Ciro de Quadros recently co-authored “Reducing the global burden of congenital rubella syndrome,” which appeared in the September 29 edition of The Lancet.

Research Publications

On October 25, the open-access journal, PLoS NTDs, celebrated its fifth anniversary. To commemorate this great achievement, the journal compiled editorials and research papers published over the last five years to create a collection called “The Geopolitics of NTDs.” Recent articles published in PLoS NTDs by Dr. Peter Hotez include “Neglected Tropical Diseases as Hidden Causes of Cardiovascular Disease” and ““Ground Zero" for the High Prevalence Neglected Tropical Diseases.”

Dr. Peter Hotez co-authored “Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects”, which appears in the September issue of Expert Review of Vaccines.

In a special edition of Vaccine released on April 24, Sabin President, Dr. Peter Hotez, and Sabin Executive Vice President, Dr. Ciro de Quadros, share their insights on global health innovations and advancements since the eradication of smallpox was certified by the World Health Assembly in 1980.


To reduce needless human suffering from vaccine preventable and neglected tropical diseases through innovative vaccine research and development; and to advocate for improved access to vaccines and essential medicines for citizens around the globe.

Sabin Vaccine Institute2000 Pennsylvania Ave N.W., Suite 7100 | Washington, DC 20006

t. (202) 842-5025